PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by educational grants from Eisai, Inc. and Merck Sharp & Dohme Corp.

TWEETORIAL FOCUS

This activity will examine the synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced Renal Cell Carcinoma (RCC) and discuss the safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting

PROGRAM OVERVIEW

The standards of care for advanced renal cell carcinoma (aRCC) have been evolving at an ever-accelerating pace over the last 20 years. Improvements in the understanding of the immunogenic nature and pathogenic drivers of this disease uncovered synergistic mechanisms between immunotherapies and antiangiogenic treatments that were previously used in single-agent treatment strategies. This led to the new “gold standard” of first-line treatment for aRCC, which is to combine immuno-oncology (IO) using the immune checkpoint inhibitors (ICIs) and antiangiogenic tyrosine kinase inhibitors (TKIs) that block vascular endothelial growth factor and its receptors. This combination strategy has extended progression-free survival and overall survival beyond what could previously be hoped for with TKI or ICI monotherapy. Determining which patient should receive which combination has become a complex question with no clear consensus. As additional combination strategies advance in clinical trials, the question gets ever-more complicated. This program will increase your ability to assess the efficacy and safety data from new and emerging combinations and aid your treatment decision making process for these patients.

FACULTY

Moshe C. Ornstein, MD, MA Assistant Professor of Medicine Cleveland Clinic Lerner College of Medicine Associate Staff, Genitourinary Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio

Sumanta K. Pal, MD, FASCO Professor, Department of Medical Oncology Co-Director, Kidney Cancer Program City of Hope Comprehensive Cancer Center Duarte, California

Brian I. Rini, MD, FASCO Ingram Professor of Medicine Vanderbilt University Medical Center Chief of Clinical Trials Vanderbilt-Ingram Cancer Center Nashville, Tennessee

Release date: December 13, 2021 Expiration date: December 13, 2022 Estimated time to complete activity: 15 minutes

TARGET AUDIENCE

This educational activity has been designed to meet the needs of oncologists, pathologists, histologists, nephrologists, urologists, nurse practitioners, physician’s assistants, nurses, pharmacists, fellows, and other professionals involved in the management of patients with RCC particularly in the community setting.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

ARTICULATE the rationale for synergistic efficacy between immuno-oncology therapies and antiangiogenic targeted treatments with their combined therapeutic applicability to advanced RCC
COMPARE the efficacy and safety findings that emerged from phase 3 clinical trials supporting the approvals of combination strategies that are now embraced as the standard of care for treating advanced RCC in the first-line setting
EVALUATE combination therapies recommended by the most recent NCCN clinical practice guidelines as first-line treatments for your patients advanced RCC

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 13, 2021 to December 13, 2022, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education Accreditation Statement Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities: Moshe C. Ornstein, MD, MA Consulting Fees: Aveo, Bristol Myers Squibb, Calithera, Eisai, Exelixis, Merck, Pfizer Fees for Non-CME/CE Services: Bristol Myers Squibb Sumanta K. Pal, MD, FASCO has no real or apparent conflicts of interest to disclose. Brian Rini, MD, FASCO Consulting Fees: 3DMedicines, Alkermes, Aveo, Compugen, Corvus, Eisai, Shionogi, Synthorx Research Funding (Institution): AstraZeneca, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Mirati Therapeutics, Seattle Genetics, Taris Consulting Fees/Research Funding (Institution): Aravive, Arrowhead Pharmaceuticals, Bristol-Myers Squibb, Genentech-Roche, GlaxoSmithKline, Pfizer, Merck, Surface Oncology Stock: PTC Therapeutics The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Single Agent Samba? Doublet Dance? Mambo Combo? Mastering the Rhythm of Treatment Selection and Sequencing in RCC – Tweetorial #2